A post-mortem study only allows one time point to be evaluated, and we are measuring gene and protein expression following severe chronic illness of different durations and prolonged treatment with different antipsychotics.39 However, these studies provide a basis for interpreting changes seen in in vivo studies in schizophrenia patients and the putative clues they provide to pathophysiology, and potential therapeutic targets beyond DRD2 antagonism can be followed up in preclinical models of dopamine dysregulation. This evidence concerns the gene DRD2 and schizophrenia.